2.Oh DY, et al. Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. 2025...
1. Oh DY, et al. Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)2024 ESM...
1.Oh DY, He AR, Qin S, et al. Three-year survival, safety and extended long-term survivor analysis from the phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer. Ann Oncol. 2024;35(suppl 1):S117. doi:10.1016/j.annonc.2024.05.285 2.Oh DY, Ruth He A, Qin...
4. Takuji Okusaka, et al. 93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study. ESMO Asia Congress 2022. Annals of Oncology (2022) 33 (suppl_9): S1454-S1484. 10.1...
2. Do-Youn Oh, et al. 78P - Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). ESMO Asia Congress 2022. Annals of Oncology (2022) 33...
1. Toyoda H, et al. Improved survival of viral hepatocellular carcinoma but not non-viral hepatocellular carcinoma from 2000 to 2020: A multi-centre cohort study of 6007 patients from high-volume academic centres in Japan. Aliment Pharmacol Ther. 2022; 56: 694– 701. ...
Background: TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study evaluating the efficacy and safety of durvalumab (D) in combination with (+) gemcitabine and cisplatin (GC) as first-line treatment for patients (pts) with advanced biliary tract cancer (BTC).1 D + ...
The historical study on which the gemcitabine-cisplatin regimen was based was the ABC-02 trial. In that trial, patients were treated for 6 months with chemotherapy and then followed. In some parts of the world, that’s the standard. In the United States, oftentimes we treat as long as ...
2.Oh DY, et al. Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. 2025 ASCO GI. Abstract 625. ...
1. Oh DY, et al. Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)2024 ESMO ASIA 135P. 2. Oh DY, He AR, Bouattour M, et al. Durvalumab or plac...